# Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

> **NCT00705536** · PHASE1 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 26 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Humalog
- **DRUG:** Humulin-R
- **DRUG:** Recombinant human hyaluronidase PH20 (rHuPH20)

## Key facts

- **NCT ID:** NCT00705536
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705536, "Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00705536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*